Evidence map›Paper›PMID 41469706›Full record

ArticleVirology journal2025

Immunogenicity analyses and indirect ELISA application of a chimeric virus-like particle presenting a highly conserved peptide of Akabane virus Gc protein.

Jingjing Wang, Fang Wei, Ruyang Yu, Dongjie Chen, Shaoqiang Wu

Abstract read
In one paragraph

Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jingjing WangInstitute of Animal Inspection and Quarantine, Chinese Academy of Quality and Inspection & Testing, 100176, Beijing, China.
Fang WeiInstitute of Animal Inspection and Quarantine, Chinese Academy of Quality and Inspection & Testing, 100176, Beijing, China.
Ruyang YuInstitute of Animal Inspection and Quarantine, Chinese Academy of Quality and Inspection & Testing, 100176, Beijing, China.
Dongjie ChenInstitute of Animal Inspection and Quarantine, Chinese Academy of Quality and Inspection & Testing, 100176, Beijing, China. chendongjie1212@163.com.
Shaoqiang WuInstitute of Animal Inspection and Quarantine, Chinese Academy of Quality and Inspection & Testing, 100176, Beijing, China. sqwu@sina.com.

Funding

Beijing Natural Science Foundation 6254044Fundamental Research Funds of the Chinese Academy of Quality and Inspection & Testing 2024JK002
6 · The paper itself

Abstract

backgroundAkabane virus (AKAV) is the causative agent of an economically significant disease in ruminants, manifested notably by outbreaks of abortion and congenital abnormalities. Vaccination stands as the primary defense against this disease. However, the development of safer, more stable, and efficient AKAV vaccines, including epitope-based designs, remains unexplored. Prior work by our group has pinpointed a neutralizing epitope,

methodsWe produced and verified a novel virus-like particle (VLP) by incorporating the neutralizing epitope

resultsThe successful construction of VLP expressing the AKAV epitope was confirmed by using SDS-PAGE, followed by Western blot (WB) and transmission electron microscopy (TEM). Indirect ELISA results indicated that antisera from immunized mice contained antibodies specific to the AKAV Gc protein. Furthermore, neutralization assays demonstrated that the antisera could effectively neutralize AKAV in vitro and inhibit its replication in BHK-21 cells. The developed VLP-based indirect ELISA method successfully identified AKAV antibody-positive serum, with a detection sensitivity of up to a 1:1600 serum dilution.

conclusionsIn conclusion, we successfully constructed a VLP presenting the highly conserved neutralizing epitope of AKAV. This VLP is proved to be immunogenic and can serve as an effective coating antigen to establish an indirect ELISA method for AKAV detection. Collectively, our findings provide proof-of-concept for this epitope-presenting VLP as a promising candidate in the pursuit of a safe and effective epitope-based vaccine against AKAV and also highlight its utility as a diagnostic antigen for serological detection.

Indexed as

Bunyaviridae InfectionsOrthobunyavirusVaccines, Virus-Like ParticleAnimalsAntibodies, NeutralizingAntibodies, ViralEnzyme-Linked Immunosorbent AssayEpitopesFemaleHepatitis B Core AntigensImmunogenicity, VaccineMiceMice, Inbred BALB CViral VaccinesAntibodies, NeutralizingAntibodies, ViralEpitopesHepatitis B Core AntigensVaccines, Virus-Like ParticleViral VaccinesAkabane virusImmunogenicity analysesIndirect ELISAPeptide of Gc proteinVirus-like particle

Identifiers

PMID41469706
PMCPMC12859939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.